| Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ... The Lancet 375 (9724), 1437-1446, 2010 | 1328 | 2010 |
| Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer DC Danila, G Heller, GA Gignac, R Gonzalez-Espinoza, A Anand, ... Clinical cancer research 13 (23), 7053-7058, 2007 | 810 | 2007 |
| High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants P Razavi, BT Li, DN Brown, B Jung, E Hubbell, R Shen, W Abida, K Juluru, ... Nature medicine 25 (12), 1928-1937, 2019 | 593 | 2019 |
| Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer DC Danila, MJ Morris, JS De Bono, CJ Ryan, SR Denmeade, MR Smith, ... Journal of Clinical Oncology 28 (9), 1496-1501, 2010 | 541 | 2010 |
| Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer DR Shaffer, MA Leversha, DC Danila, O Lin, R Gonzalez-Espinoza, B Gu, ... Clinical cancer research 13 (7), 2023-2029, 2007 | 416 | 2007 |
| Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer MA Leversha, J Han, Z Asgari, DC Danila, O Lin, R Gonzalez-Espinoza, ... Clinical cancer research 15 (6), 2091-2097, 2009 | 255 | 2009 |
| TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate DC Danila, A Anand, CC Sung, G Heller, MA Leversha, L Cao, H Lilja, ... European urology 60 (5), 897-904, 2011 | 218 | 2011 |
| Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and … P Helo, AM Cronin, DC Danila, S Wenske, R Gonzalez-Espinoza, ... Clinical chemistry 55 (4), 765-773, 2009 | 168 | 2009 |
| Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC … HI Scher, G Heller, A Molina, TS Kheoh, G Attard, J Moreira, SK Sandhu, ... Journal of Clinical Oncology 29 (18_suppl), LBA4517-LBA4517, 2011 | 152 | 2011 |
| A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer D Rathkopf, BY Wong, RW Ross, A Anand, E Tanaka, MM Woo, J Hu, ... Cancer chemotherapy and pharmacology 66, 181-189, 2010 | 133 | 2010 |
| A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study RW Ross, MD Galsky, HI Scher, J Magidson, K Wassmann, GSM Lee, ... The lancet oncology 13 (11), 1105-1113, 2012 | 128 | 2012 |
| Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a … AJ Armstrong, A Anand, L Edenbrandt, E Bondesson, A Bjartell, ... JAMA oncology 4 (7), 944-951, 2018 | 117 | 2018 |
| Androgen receptor expression is associated with prostate cancer‐specific survival in castrate patients with metastatic disease MJ Donovan, I Osman, FM Khan, Y Vengrenyuk, P Capodieci, ... BJU international 105 (4), 462-467, 2010 | 100 | 2010 |
| Analytic and clinical validation of a prostate cancer–enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival DC Danila, A Anand, N Schultz, G Heller, M Wan, CC Sung, C Dai, ... European urology 65 (6), 1191-1197, 2014 | 93 | 2014 |
| Analytic validation of the automated bone scan index as an imaging biomarker to standardize quantitative changes in bone scans of patients with metastatic prostate cancer A Anand, MJ Morris, R Kaboteh, L Båth, M Sadik, P Gjertsson, M Lomsky, ... Journal of Nuclear Medicine 57 (1), 41-45, 2016 | 84 | 2016 |
| Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 … HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ... Lancet 375 (9724), 1437-1446, 2010 | 84 | 2010 |
| Clinical validity of detecting circulating tumor cells by AdnaTest assay compared with direct detection of tumor mRNA in stabilized whole blood, as a biomarker predicting … DC Danila, A Samoila, C Patel, N Schreiber, A Herkal, A Anand, D Bastos, ... The Cancer Journal 22 (5), 315-320, 2016 | 80 | 2016 |
| Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide A Anand, MJ Morris, SM Larson, D Minarik, A Josefsson, JT Helgstrand, ... EJNMMI research 6, 1-7, 2016 | 67 | 2016 |
| Cartilage oligomeric matrix protein promotes prostate cancer progression by enhancing invasion and disrupting intracellular calcium homeostasis E Englund, G Canesin, KS Papadakos, N Vishnu, E Persson, B Reitsma, ... Oncotarget 8 (58), 98298, 2017 | 58 | 2017 |
| Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC) HI Scher, TM Beer, CS Higano, M Taplin, E Efstathiou, A Anand, D Hung, ... Journal of Clinical Oncology 27 (15_suppl), 5011-5011, 2009 | 58 | 2009 |
